Advertisement
 
YOU ARE HERE: LAT HomeCollectionsPlavix Drug
IN THE NEWS

Plavix Drug

FEATURED ARTICLES
BUSINESS
May 31, 2007 | From Times Wire Services
Bristol-Myers Squibb Co. was charged with lying to federal regulators over the bungled patent settlement for the drug maker's blood-thinner Plavix, a planned first step toward it pleading guilty in the case. A two-count criminal charge was filed in federal court in Washington. The company said May 10 that it would plead guilty to two counts of making false statements and pay a $1-million fine.
ARTICLES BY DATE
BUSINESS
June 20, 2007 | From the Associated Press
A Canadian company's generic version of the blood thinner Plavix has been blocked from the U.S. market until at least 2011. U.S. District Judge Sidney H. Stein said Tuesday that Apotex Inc. had failed to prove during a three-week trial in New York this year that the patent protecting Plavix from competitors was invalid. Apotex said it would file an immediate appeal with the U.S. Court of Appeals for the Federal Circuit in Washington.
Advertisement
BUSINESS
June 20, 2007 | From the Associated Press
A Canadian company's generic version of the blood thinner Plavix has been blocked from the U.S. market until at least 2011. U.S. District Judge Sidney H. Stein said Tuesday that Apotex Inc. had failed to prove during a three-week trial in New York this year that the patent protecting Plavix from competitors was invalid. Apotex said it would file an immediate appeal with the U.S. Court of Appeals for the Federal Circuit in Washington.
BUSINESS
June 12, 2007 | From the Associated Press
Drug maker Bristol-Myers Squibb Co. said Monday that it pleaded guilty to two counts of making false statements to the Federal Trade Commission regarding the firm's botched settlement with generic drug maker Apotex Inc. over the blood thinner Plavix. As a result, Bristol-Myers will pay a fine of $1 million, resolving a Justice Department probe.
BUSINESS
January 19, 2007 | From Bloomberg News
Bristol-Myers Squibb Co. will ask a U.S. court to stop generic versions of its bestselling drug Plavix, four months after ousting its chief executive for bungling a deal to delay copycat versions of the medicine. Bristol-Myers and Sanofi-Aventis, France's biggest drug maker, will urge a federal judge to uphold the patent on Plavix, a blood thinner, in a trial set to begin Monday in New York. Apotex Inc.
BUSINESS
April 4, 2007 | From Bloomberg News
Bristol-Myers Squibb Co. and Sanofi-Aventis said Tuesday that they were cooperating with demands from U.S. antitrust regulators for documents related to an unsuccessful bid last year to delay generic competition to the blood thinner Plavix. The Federal Trade Commission served the drug makers last month with formal requests for records.
BUSINESS
December 9, 2006 | From the Associated Press
A federal appeals court upheld Friday an injunction preventing Apotex Corp. from selling its generic version of Plavix, a blockbuster blood thinner marketed by Bristol-Myers Squibb and Sanofi-Aventis. The U.S. Court of Appeals for the Federal Circuit in Washington upheld the injunction issued in August by the U.S. District Court for the Southern District of New York.
BUSINESS
June 12, 2007 | From the Associated Press
Drug maker Bristol-Myers Squibb Co. said Monday that it pleaded guilty to two counts of making false statements to the Federal Trade Commission regarding the firm's botched settlement with generic drug maker Apotex Inc. over the blood thinner Plavix. As a result, Bristol-Myers will pay a fine of $1 million, resolving a Justice Department probe.
BUSINESS
September 4, 2002 | Bloomberg News
Bristol-Myers Squibb Co. moved closer to Food and Drug Administration approval of the Abilify schizophrenia drug, which may be the company's next big product. The drug maker said it is in discussions with the FDA, which sent a letter indicating that the product may be approved after certain issues are resolved. The company didn't reveal what concerns the FDA raised in the letter. Bristol-Myers said it expects FDA approval of Abilify this year.
BUSINESS
August 9, 2006 | From Bloomberg News
Sanofi-Aventis and Bristol-Myers Squibb Co. are facing generic competition in the U.S. for their top-selling Plavix blood-thinning pill five years earlier than planned. Apotex Inc., a closely held Canadian maker of generic drugs, said it started shipping cheaper copies Tuesday. Plavix is the world's second-best-selling pill. Sanofi and Bristol-Myers lost a bid Monday in U.S. court to block the sales. At stake for Paris-based Sanofi and New York-based Bristol-Myers is $6.
BUSINESS
May 31, 2007 | From Times Wire Services
Bristol-Myers Squibb Co. was charged with lying to federal regulators over the bungled patent settlement for the drug maker's blood-thinner Plavix, a planned first step toward it pleading guilty in the case. A two-count criminal charge was filed in federal court in Washington. The company said May 10 that it would plead guilty to two counts of making false statements and pay a $1-million fine.
BUSINESS
April 4, 2007 | From Bloomberg News
Bristol-Myers Squibb Co. and Sanofi-Aventis said Tuesday that they were cooperating with demands from U.S. antitrust regulators for documents related to an unsuccessful bid last year to delay generic competition to the blood thinner Plavix. The Federal Trade Commission served the drug makers last month with formal requests for records.
BUSINESS
January 19, 2007 | From Bloomberg News
Bristol-Myers Squibb Co. will ask a U.S. court to stop generic versions of its bestselling drug Plavix, four months after ousting its chief executive for bungling a deal to delay copycat versions of the medicine. Bristol-Myers and Sanofi-Aventis, France's biggest drug maker, will urge a federal judge to uphold the patent on Plavix, a blood thinner, in a trial set to begin Monday in New York. Apotex Inc.
BUSINESS
December 9, 2006 | From the Associated Press
A federal appeals court upheld Friday an injunction preventing Apotex Corp. from selling its generic version of Plavix, a blockbuster blood thinner marketed by Bristol-Myers Squibb and Sanofi-Aventis. The U.S. Court of Appeals for the Federal Circuit in Washington upheld the injunction issued in August by the U.S. District Court for the Southern District of New York.
Los Angeles Times Articles
|